Technical Analysis for PRLD - Prelude Therapeutics Incorporated
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Overbought Stochastic | Strength | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
20 DMA Support | Bullish | -1.90% | |
Pocket Pivot | Bullish Swing Setup | -1.90% | |
Reversal New Highs Setup | Bullish Swing Setup | -1.90% | |
Stochastic Reached Overbought | Strength | -1.90% | |
Outside Day | Range Expansion | -1.90% | |
Overbought Stochastic | Strength | -1.90% | |
Gapped Down | Weakness | -1.90% | |
Earnings Movers | Other | 4.26% |
Alert | Time |
---|---|
Up 3% | about 12 hours ago |
60 Minute Opening Range Breakout | about 12 hours ago |
Up 2% | about 12 hours ago |
60 Minute Opening Range Breakdown | about 16 hours ago |
Down 2 % | about 16 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 03/13/2024
Prelude Therapeutics Incorporated Description
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Solid Tumors Lymphoma Blastoma Protein Kinase Inhibitor Glioblastoma Tyrosine Kinase Receptors Small Molecule Therapies Glioblastoma Multiforme Phosphoinositide 3 Kinase Inhibitor
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 8.565 |
52 Week Low | 1.66 |
Average Volume | 79,585 |
200-Day Moving Average | 3.69 |
50-Day Moving Average | 3.75 |
20-Day Moving Average | 4.26 |
10-Day Moving Average | 4.38 |
Average True Range | 0.39 |
RSI (14) | 60.32 |
ADX | 35.26 |
+DI | 27.37 |
-DI | 12.51 |
Chandelier Exit (Long, 3 ATRs) | 3.75 |
Chandelier Exit (Short, 3 ATRs) | 4.56 |
Upper Bollinger Bands | 4.77 |
Lower Bollinger Band | 3.75 |
Percent B (%b) | 0.89 |
BandWidth | 23.97 |
MACD Line | 0.25 |
MACD Signal Line | 0.22 |
MACD Histogram | 0.0253 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 5.13 | ||||
Resistance 3 (R3) | 5.17 | 5.05 | 5.05 | ||
Resistance 2 (R2) | 5.05 | 4.93 | 5.03 | 5.02 | |
Resistance 1 (R1) | 4.85 | 4.85 | 4.79 | 4.81 | 5.00 |
Pivot Point | 4.73 | 4.73 | 4.70 | 4.71 | 4.73 |
Support 1 (S1) | 4.53 | 4.61 | 4.47 | 4.49 | 4.30 |
Support 2 (S2) | 4.41 | 4.53 | 4.39 | 4.28 | |
Support 3 (S3) | 4.21 | 4.41 | 4.25 | ||
Support 4 (S4) | 4.17 |